Table of Contents 1 Peptide and Anticoagulant Drugs Market Overview 1.1 Product Overview and Scope of Peptide and Anticoagulant Drugs 1.2 Peptide and Anticoagulant Drugs Segment by Type 1.2.1 Global Peptide and Anticoagulant Drugs Sales Growth Rate Comparison by Type (2021-2026) 1.2.2 Hormonal 1.2.3 Antibiotic 1.2.4 ACE Inhibitor 1.2.5 Antifungal 1.2.6 Others 1.3 Peptide and Anticoagulant Drugs Segment by Application 1.3.1 Peptide and Anticoagulant Drugs Sales Comparison by Application: 2020 VS 2026 1.3.2 Diabetes 1.3.3 Infectious Diseases 1.3.4 Cancer 1.3.5 Osteoporosis 1.3.6 Cardiology 1.3.7 Gynecology 1.3.8 Other Applications 1.4 Global Peptide and Anticoagulant Drugs Market Size Estimates and Forecasts 1.4.1 Global Peptide and Anticoagulant Drugs Revenue 2015-2026 1.4.2 Global Peptide and Anticoagulant Drugs Sales 2015-2026 1.4.3 Peptide and Anticoagulant Drugs Market Size by Region: 2020 Versus 2026 2 Global Peptide and Anticoagulant Drugs Market Competition by Manufacturers 2.1 Global Peptide and Anticoagulant Drugs Sales Market Share by Manufacturers (2015-2020) 2.2 Global Peptide and Anticoagulant Drugs Revenue Share by Manufacturers (2015-2020) 2.3 Global Peptide and Anticoagulant Drugs Average Price by Manufacturers (2015-2020) 2.4 Manufacturers Peptide and Anticoagulant Drugs Manufacturing Sites, Area Served, Product Type 2.5 Peptide and Anticoagulant Drugs Market Competitive Situation and Trends 2.5.1 Peptide and Anticoagulant Drugs Market Concentration Rate 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 2.7 Primary Interviews with Key Peptide and Anticoagulant Drugs Players (Opinion Leaders) 3 Peptide and Anticoagulant Drugs Retrospective Market Scenario by Region 3.1 Global Peptide and Anticoagulant Drugs Retrospective Market Scenario in Sales by Region: 2015-2020 3.2 Global Peptide and Anticoagulant Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020 3.3 North America Peptide and Anticoagulant Drugs Market Facts & Figures by Country 3.3.1 North America Peptide and Anticoagulant Drugs Sales by Country 3.3.2 North America Peptide and Anticoagulant Drugs Sales by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Peptide and Anticoagulant Drugs Market Facts & Figures by Country 3.4.1 Europe Peptide and Anticoagulant Drugs Sales by Country 3.4.2 Europe Peptide and Anticoagulant Drugs Sales by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Peptide and Anticoagulant Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Peptide and Anticoagulant Drugs Sales by Region 3.5.2 Asia Pacific Peptide and Anticoagulant Drugs Sales by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Peptide and Anticoagulant Drugs Market Facts & Figures by Country 3.6.1 Latin America Peptide and Anticoagulant Drugs Sales by Country 3.6.2 Latin America Peptide and Anticoagulant Drugs Sales by Country 3.6.3 Mexico 3.6.3 Brazil 3.6.3 Argentina 3.7 Middle East and Africa Peptide and Anticoagulant Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Peptide and Anticoagulant Drugs Sales by Country 3.7.2 Middle East and Africa Peptide and Anticoagulant Drugs Sales by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Peptide and Anticoagulant Drugs Historic Market Analysis by Type 4.1 Global Peptide and Anticoagulant Drugs Sales Market Share by Type (2015-2020) 4.2 Global Peptide and Anticoagulant Drugs Revenue Market Share by Type (2015-2020) 4.3 Global Peptide and Anticoagulant Drugs Price Market Share by Type (2015-2020) 4.4 Global Peptide and Anticoagulant Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Peptide and Anticoagulant Drugs Historic Market Analysis by Application 5.1 Global Peptide and Anticoagulant Drugs Sales Market Share by Application (2015-2020) 5.2 Global Peptide and Anticoagulant Drugs Revenue Market Share by Application (2015-2020) 5.3 Global Peptide and Anticoagulant Drugs Price by Application (2015-2020) 6 Company Profiles and Key Figures in Peptide and Anticoagulant Drugs Business 6.1 Celsus 6.1.1 Corporation Information 6.1.2 Celsus Description, Business Overview and Total Revenue 6.1.3 Celsus Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.1.4 Celsus Products Offered 6.1.5 Celsus Recent Development 6.2 Baxter 6.2.1 Baxter Peptide and Anticoagulant Drugs Production Sites and Area Served 6.2.2 Baxter Description, Business Overview and Total Revenue 6.2.3 Baxter Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.2.4 Baxter Products Offered 6.2.5 Baxter Recent Development 6.3 Hemmo Pharma 6.3.1 Hemmo Pharma Peptide and Anticoagulant Drugs Production Sites and Area Served 6.3.2 Hemmo Pharma Description, Business Overview and Total Revenue 6.3.3 Hemmo Pharma Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.3.4 Hemmo Pharma Products Offered 6.3.5 Hemmo Pharma Recent Development 6.4 Biofer 6.4.1 Biofer Peptide and Anticoagulant Drugs Production Sites and Area Served 6.4.2 Biofer Description, Business Overview and Total Revenue 6.4.3 Biofer Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Biofer Products Offered 6.4.5 Biofer Recent Development 6.5 Wockhardt 6.5.1 Wockhardt Peptide and Anticoagulant Drugs Production Sites and Area Served 6.5.2 Wockhardt Description, Business Overview and Total Revenue 6.5.3 Wockhardt Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.5.4 Wockhardt Products Offered 6.5.5 Wockhardt Recent Development 6.6 AmbioPharm 6.6.1 AmbioPharm Peptide and Anticoagulant Drugs Production Sites and Area Served 6.6.2 AmbioPharm Description, Business Overview and Total Revenue 6.6.3 AmbioPharm Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.6.4 AmbioPharm Products Offered 6.6.5 AmbioPharm Recent Development 6.7 Bachem 6.6.1 Bachem Peptide and Anticoagulant Drugs Production Sites and Area Served 6.6.2 Bachem Description, Business Overview and Total Revenue 6.6.3 Bachem Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.4.4 Bachem Products Offered 6.7.5 Bachem Recent Development 6.8 Sun Pharmaceutical Industries 6.8.1 Sun Pharmaceutical Industries Peptide and Anticoagulant Drugs Production Sites and Area Served 6.8.2 Sun Pharmaceutical Industries Description, Business Overview and Total Revenue 6.8.3 Sun Pharmaceutical Industries Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.8.4 Sun Pharmaceutical Industries Products Offered 6.8.5 Sun Pharmaceutical Industries Recent Development 6.9 Pfizer 6.9.1 Pfizer Peptide and Anticoagulant Drugs Production Sites and Area Served 6.9.2 Pfizer Description, Business Overview and Total Revenue 6.9.3 Pfizer Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.9.4 Pfizer Products Offered 6.9.5 Pfizer Recent Development 6.10 Abbott Laboratories 6.10.1 Abbott Laboratories Peptide and Anticoagulant Drugs Production Sites and Area Served 6.10.2 Abbott Laboratories Description, Business Overview and Total Revenue 6.10.3 Abbott Laboratories Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.10.4 Abbott Laboratories Products Offered 6.10.5 Abbott Laboratories Recent Development 6.11 Leo Pharma 6.11.1 Leo Pharma Peptide and Anticoagulant Drugs Production Sites and Area Served 6.11.2 Leo Pharma Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.11.3 Leo Pharma Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.11.4 Leo Pharma Products Offered 6.11.5 Leo Pharma Recent Development 6.12 Aspen 6.12.1 Aspen Peptide and Anticoagulant Drugs Production Sites and Area Served 6.12.2 Aspen Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.12.3 Aspen Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.12.4 Aspen Products Offered 6.12.5 Aspen Recent Development 6.13 Takeda 6.13.1 Takeda Peptide and Anticoagulant Drugs Production Sites and Area Served 6.13.2 Takeda Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.13.3 Takeda Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.13.4 Takeda Products Offered 6.13.5 Takeda Recent Development 6.14 Teva 6.14.1 Teva Peptide and Anticoagulant Drugs Production Sites and Area Served 6.14.2 Teva Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.14.3 Teva Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.14.4 Teva Products Offered 6.14.5 Teva Recent Development 6.15 Sanofi 6.15.1 Sanofi Peptide and Anticoagulant Drugs Production Sites and Area Served 6.15.2 Sanofi Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.15.3 Sanofi Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.15.4 Sanofi Products Offered 6.15.5 Sanofi Recent Development 6.16 Eli Lilly 6.16.1 Eli Lilly Peptide and Anticoagulant Drugs Production Sites and Area Served 6.16.2 Eli Lilly Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.16.3 Eli Lilly Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.16.4 Eli Lilly Products Offered 6.16.5 Eli Lilly Recent Development 6.17 Novo Nordisk 6.17.1 Novo Nordisk Peptide and Anticoagulant Drugs Production Sites and Area Served 6.17.2 Novo Nordisk Peptide and Anticoagulant Drugs Description, Business Overview and Total Revenue 6.17.3 Novo Nordisk Peptide and Anticoagulant Drugs Sales, Revenue and Gross Margin (2015-2020) 6.17.4 Novo Nordisk Products Offered 6.17.5 Novo Nordisk Recent Development 7 Peptide and Anticoagulant Drugs Manufacturing Cost Analysis 7.1 Peptide and Anticoagulant Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Raw Materials Price Trend 7.1.3 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Peptide and Anticoagulant Drugs 7.4 Peptide and Anticoagulant Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Peptide and Anticoagulant Drugs Distributors List 8.3 Peptide and Anticoagulant Drugs Customers 9 Market Dynamics 9.1 Market Trends 9.2 Opportunities and Drivers 9.3 Challenges 9.4 Porter's Five Forces Analysis 10 Global Market Forecast 10.1 Global Peptide and Anticoagulant Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Peptide and Anticoagulant Drugs by Type (2021-2026) 10.1.2 Global Forecasted Revenue of Peptide and Anticoagulant Drugs by Type (2021-2026) 10.2 Peptide and Anticoagulant Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Peptide and Anticoagulant Drugs by Application (2021-2026) 10.2.2 Global Forecasted Revenue of Peptide and Anticoagulant Drugs by Application (2021-2026) 10.3 Peptide and Anticoagulant Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Peptide and Anticoagulant Drugs by Region (2021-2026) 10.3.2 Global Forecasted Revenue of Peptide and Anticoagulant Drugs by Region (2021-2026) 10.4 North America Peptide and Anticoagulant Drugs Estimates and Projections (2021-2026) 10.5 Europe Peptide and Anticoagulant Drugs Estimates and Projections (2021-2026) 10.6 Asia Pacific Peptide and Anticoagulant Drugs Estimates and Projections (2021-2026) 10.7 Latin America Peptide and Anticoagulant Drugs Estimates and Projections (2021-2026) 10.8 Middle East and Africa Peptide and Anticoagulant Drugs Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Peptide and Anticoagulant Drugs Sales (K Units) Growth Rate Comparison by Type (2015-2026) Table 2. Global Peptide and Anticoagulant Drugs Sales (K Units) Comparison by Application: 2020 VS 2026 Table 3. Global Peptide and Anticoagulant Drugs Market Size by Type (K Units) (US$ Million) (2020 VS 2026) Table 4. Global Key Peptide and Anticoagulant Drugs Manufacturers Covered in This Study Table 5. Global Peptide and Anticoagulant Drugs Sales (K Units) by Manufacturers (2015-2020) Table 6. Global Peptide and Anticoagulant Drugs Sales Share by Manufacturers (2015-2020) Table 7. Global Peptide and Anticoagulant Drugs Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Peptide and Anticoagulant Drugs Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Peptide and Anticoagulant Drugs Average Price (USD/Unit) of Key Manufacturers (2015-2020) Table 10. Manufacturers Peptide and Anticoagulant Drugs Sales Sites and Area Served Table 11. Manufacturers Peptide and Anticoagulant Drugs Product Types Table 12. Global Peptide and Anticoagulant Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Peptide and Anticoagulant Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide and Anticoagulant Drugs as of 2019) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Peptide and Anticoagulant Drugs Players Table 16. Global Peptide and Anticoagulant Drugs Sales (K Units) by Region (2015-2020) Table 17. Global Peptide and Anticoagulant Drugs Sales Market Share by Region (2015-2020) Table 18. Global Peptide and Anticoagulant Drugs Revenue (Million US$) by Region (2015-2020) Table 19. Global Peptide and Anticoagulant Drugs Revenue Market Share by Region (2015-2020) Table 20. North America Peptide and Anticoagulant Drugs Sales by Country (2015-2020) (K Units) Table 21. North America Peptide and Anticoagulant Drugs Sales Market Share by Country (2015-2020) Table 22. North America Peptide and Anticoagulant Drugs Revenue by Country (2015-2020) (US$ Million) Table 23. North America Peptide and Anticoagulant Drugs Revenue Market Share by Country (2015-2020) Table 24. Europe Peptide and Anticoagulant Drugs Sales by Country (2015-2020) (K Units) Table 25. Europe Peptide and Anticoagulant Drugs Sales Market Share by Country (2015-2020) Table 26. Europe Peptide and Anticoagulant Drugs Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Peptide and Anticoagulant Drugs Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Peptide and Anticoagulant Drugs Sales by Region (2015-2020) (K Units) Table 29. Asia Pacific Peptide and Anticoagulant Drugs Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Peptide and Anticoagulant Drugs Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Peptide and Anticoagulant Drugs Revenue Market Share by Region (2015-2020) Table 32. Latin America Peptide and Anticoagulant Drugs Sales by Country (2015-2020) (K Units) Table 33. Latin America Peptide and Anticoagulant Drugs Sales Market Share by Country (2015-2020) Table 34. Latin America Peptide and Anticoagulant Drugs Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Peptide and Anticoagulant Drugs Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Peptide and Anticoagulant Drugs Sales by Country (2015-2020) (K Units) Table 37. Middle East and Africa Peptide and Anticoagulant Drugs Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Peptide and Anticoagulant Drugs Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Peptide and Anticoagulant Drugs Revenue Market Share by Country (2015-2020) Table 40. Global Peptide and Anticoagulant Drugs Sales (K Units) by Type (2015-2020) Table 41. Global Peptide and Anticoagulant Drugs Sales Share by Type (2015-2020) Table 42. Global Peptide and Anticoagulant Drugs Revenue (Million US$) by Type (2015-2020) Table 43. Global Peptide and Anticoagulant Drugs Revenue Share by Type (2015-2020) Table 44. Global Peptide and Anticoagulant Drugs Price (USD/Unit) by Type (2015-2020) Table 45. Global Peptide and Anticoagulant Drugs Sales (K Units) by Application (2015-2020) Table 46. Global Peptide and Anticoagulant Drugs Sales Market Share by Application (2015-2020) Table 47. Global Peptide and Anticoagulant Drugs Sales Growth Rate by Application (2015-2020) Table 48. Celsus Peptide and Anticoagulant Drugs Corporation Information Table 49. Celsus Description and Business Overview Table 50. Celsus Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 51. Celsus Main Product Table 52. Celsus Recent Development Table 53. Baxter Peptide and Anticoagulant Drugs Corporation Information Table 54. Baxter Corporation Information Table 55. Baxter Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 56. Baxter Main Product Table 57. Baxter Recent Development Table 58. Hemmo Pharma Peptide and Anticoagulant Drugs Corporation Information Table 59. Hemmo Pharma Corporation Information Table 60. Hemmo Pharma Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 61. Hemmo Pharma Main Product Table 62. Hemmo Pharma Recent Development Table 63. Biofer Peptide and Anticoagulant Drugs Corporation Information Table 64. Biofer Corporation Information Table 65. Biofer Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 66. Biofer Main Product Table 67. Biofer Recent Development Table 68. Wockhardt Peptide and Anticoagulant Drugs Corporation Information Table 69. Wockhardt Corporation Information Table 70. Wockhardt Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 71. Wockhardt Main Product Table 72. Wockhardt Recent Development Table 73. AmbioPharm Peptide and Anticoagulant Drugs Corporation Information Table 74. AmbioPharm Corporation Information Table 75. AmbioPharm Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 76. AmbioPharm Main Product Table 77. AmbioPharm Recent Development Table 78. Bachem Peptide and Anticoagulant Drugs Corporation Information Table 79. Bachem Corporation Information Table 80. Bachem Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 81. Bachem Main Product Table 82. Bachem Recent Development Table 83. Sun Pharmaceutical Industries Peptide and Anticoagulant Drugs Corporation Information Table 84. Sun Pharmaceutical Industries Corporation Information Table 85. Sun Pharmaceutical Industries Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 86. Sun Pharmaceutical Industries Main Product Table 87. Sun Pharmaceutical Industries Recent Development Table 88. Pfizer Peptide and Anticoagulant Drugs Corporation Information Table 89. Pfizer Corporation Information Table 90. Pfizer Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 91. Pfizer Main Product Table 92. Pfizer Recent Development Table 93. Abbott Laboratories Peptide and Anticoagulant Drugs Corporation Information Table 94. Abbott Laboratories Corporation Information Table 95. Abbott Laboratories Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 96. Abbott Laboratories Main Product Table 97. Abbott Laboratories Recent Development Table 98. Leo Pharma Peptide and Anticoagulant Drugs Corporation Information Table 99. Leo Pharma Corporation Information Table 100. Leo Pharma Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 101. Leo Pharma Main Product Table 102. Leo Pharma Recent Development Table 103. Aspen Peptide and Anticoagulant Drugs Corporation Information Table 104. Aspen Corporation Information Table 105. Aspen Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 106. Aspen Main Product Table 107. Aspen Recent Development Table 108. Takeda Peptide and Anticoagulant Drugs Corporation Information Table 109. Takeda Corporation Information Table 110. Takeda Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 111. Takeda Main Product Table 112. Takeda Recent Development Table 113. Teva Peptide and Anticoagulant Drugs Corporation Information Table 114. Teva Corporation Information Table 115. Teva Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 116. Teva Main Product Table 117. Teva Recent Development Table 118. Sanofi Peptide and Anticoagulant Drugs Corporation Information Table 119. Sanofi Corporation Information Table 120. Sanofi Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 121. Sanofi Main Product Table 122. Sanofi Recent Development Table 123. Eli Lilly Peptide and Anticoagulant Drugs Corporation Information Table 124. Eli Lilly Corporation Information Table 125. Eli Lilly Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 126. Eli Lilly Main Product Table 127. Eli Lilly Recent Development Table 128. Novo Nordisk Peptide and Anticoagulant Drugs Corporation Information Table 129. Novo Nordisk Corporation Information Table 130. Novo Nordisk Peptide and Anticoagulant Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020) Table 131. Novo Nordisk Main Product Table 132. Novo Nordisk Recent Development Table 133. Sales Base and Market Concentration Rate of Raw Material Table 134. Key Suppliers of Raw Materials Table 135. Peptide and Anticoagulant Drugs Distributors List Table 136. Peptide and Anticoagulant Drugs Customers List Table 137. Market Key Trends Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 139. Key Challenges Table 140. Global Peptide and Anticoagulant Drugs Sales (K Units) Forecast by Type (2021-2026) Table 141. Global Peptide and Anticoagulant Drugs Sales Market Share Forecast by Type (2021-2026) Table 142. Global Peptide and Anticoagulant Drugs Revenue (Million US$) Forecast by Type (2021-2026) Table 143. Global Peptide and Anticoagulant Drugs Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 144. Global Peptide and Anticoagulant Drugs Sales (K Units) Forecast by Application (2021-2026) Table 145. Global Peptide and Anticoagulant Drugs Revenue (Million US$) Forecast by Application (2021-2026) Table 146. Global Peptide and Anticoagulant Drugs Sales (K Units) Forecast by Region (2021-2026) Table 147. Global Peptide and Anticoagulant Drugs Sales Market Share Forecast by Region (2021-2026) Table 148. Global Peptide and Anticoagulant Drugs Revenue Forecast by Region (2021-2026) (US$ Million) Table 149. Global Peptide and Anticoagulant Drugs Revenue Market Share Forecast by Region (2021-2026) Table 150. Research Programs/Design for This Report Table 151. Key Data Information from Secondary Sources Table 152. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Peptide and Anticoagulant Drugs Figure 2. Global Peptide and Anticoagulant Drugs Sales Market Share by Type: 2020 VS 2026 Figure 3. Hormonal Product Picture Figure 4. Antibiotic Product Picture Figure 5. ACE Inhibitor Product Picture Figure 6. Antifungal Product Picture Figure 7. Others Product Picture Figure 8. Global Peptide and Anticoagulant Drugs Consumption Market Share by Application: 2020 VS 2026 Figure 9. Diabetes Figure 10. Infectious Diseases Figure 11. Cancer Figure 12. Osteoporosis Figure 13. Cardiology Figure 14. Gynecology Figure 15. Other Applications Figure 16. Global Peptide and Anticoagulant Drugs Market Size 2015-2026 (US$ Million) Figure 17. Global Peptide and Anticoagulant Drugs Sales Capacity (K Units) (2015-2026) Figure 18. Global Peptide and Anticoagulant Drugs Market Size Market Share by Region: 2020 Versus 2026 Figure 19. Peptide and Anticoagulant Drugs Sales Share by Manufacturers in 2020 Figure 20. Global Peptide and Anticoagulant Drugs Revenue Share by Manufacturers in 2019 Figure 21. The Global 5 and 10 Largest Players: Market Share by Peptide and Anticoagulant Drugs Revenue in 2019 Figure 22. Peptide and Anticoagulant Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 23. Global Peptide and Anticoagulant Drugs Sales Market Share by Region (2015-2020) Figure 24. Global Peptide and Anticoagulant Drugs Sales Market Share by Region in 2019 Figure 25. Global Peptide and Anticoagulant Drugs Revenue Market Share by Region (2015-2020) Figure 26. Global Peptide and Anticoagulant Drugs Revenue Market Share by Region in 2019 Figure 27. North America Peptide and Anticoagulant Drugs Sales Market Share by Country in 2019 Figure 28. North America Peptide and Anticoagulant Drugs Revenue Market Share by Country in 2019 Figure 29. U.S. Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 30. U.S. Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 31. Canada Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 32. Canada Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 33. Europe Peptide and Anticoagulant Drugs Sales Market Share by Country in 2019 Figure 34. Europe Peptide and Anticoagulant Drugs Revenue Market Share by Country in 2019 Figure 35. Germany Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 36. Germany Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 37. France Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 38. France Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 39. U.K. Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 40. U.K. Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 41. Italy Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 42. Italy Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 43. Russia Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 44. Russia Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 45. Asia Pacific Peptide and Anticoagulant Drugs Sales Market Share by Region in 2019 Figure 46. Asia Pacific Peptide and Anticoagulant Drugs Revenue Market Share by Region in 2019 Figure 47. China Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 48. China Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 49. Japan Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 50. Japan Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 51. South Korea Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 52. South Korea Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 53. India Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 54. India Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 55. Australia Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 56. Australia Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 57. Taiwan Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 58. Taiwan Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 59. Indonesia Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 60. Indonesia Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 61. Thailand Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 62. Thailand Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 63. Malaysia Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 64. Malaysia Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 65. Philippines Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 66. Philippines Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 67. Vietnam Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 68. Vietnam Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 69. Latin America Peptide and Anticoagulant Drugs Sales Market Share by Country in 2019 Figure 70. Latin America Peptide and Anticoagulant Drugs Revenue Market Share by Country in 2019 Figure 71. Mexico Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 72. Mexico Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 73. Brazil Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 74. Brazil Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 75. Argentina Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 76. Argentina Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 77. Middle East and Africa Peptide and Anticoagulant Drugs Sales Market Share by Country in 2019 Figure 78. Middle East and Africa Peptide and Anticoagulant Drugs Revenue Market Share by Country in 2019 Figure 79. Turkey Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 80. Turkey Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 81. Saudi Arabia Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 82. Saudi Arabia Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 83. U.A.E Peptide and Anticoagulant Drugs Sales Growth Rate (2015-2020) (K Units) Figure 84. U.A.E Peptide and Anticoagulant Drugs Revenue Growth Rate (2015-2020) (US$ Million) Figure 85. Sales Market Share of Peptide and Anticoagulant Drugs by Type (2015-2020) Figure 86. Sales Market Share of Peptide and Anticoagulant Drugs by Type in 2019 Figure 87. Revenue Share of Peptide and Anticoagulant Drugs by Type (2015-2020) Figure 88. Revenue Market Share of Peptide and Anticoagulant Drugs by Type in 2019 Figure 89. Global Peptide and Anticoagulant Drugs Sales Growth by Type (2015-2020) (K Units) Figure 90. Global Peptide and Anticoagulant Drugs Sales Market Share by Application (2015-2020) Figure 91. Global Peptide and Anticoagulant Drugs Sales Market Share by Application in 2019 Figure 92. Global Revenue Share of Peptide and Anticoagulant Drugs by Application (2015-2020) Figure 93. Global Revenue Share of Peptide and Anticoagulant Drugs by Application in 2020 Figure 94. Celsus Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. Baxter Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Hemmo Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. Biofer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 98. Wockhardt Total Revenue (US$ Million): 2019 Compared with 2018 Figure 99. AmbioPharm Total Revenue (US$ Million): 2019 Compared with 2018 Figure 100. Bachem Total Revenue (US$ Million): 2019 Compared with 2018 Figure 101. Sun Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018 Figure 102. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 103. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018 Figure 104. Leo Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 105. Aspen Total Revenue (US$ Million): 2019 Compared with 2018 Figure 106. Takeda Total Revenue (US$ Million): 2019 Compared with 2018 Figure 107. Teva Total Revenue (US$ Million): 2019 Compared with 2018 Figure 108. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 109. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018 Figure 110. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018 Figure 111. Price Trend of Key Raw Materials Figure 112. Manufacturing Cost Structure of Peptide and Anticoagulant Drugs Figure 113. Manufacturing Process Analysis of Peptide and Anticoagulant Drugs Figure 114. Peptide and Anticoagulant Drugs Industrial Chain Analysis Figure 115. Channels of Distribution Figure 116. Distributors Profiles Figure 117. Porter's Five Forces Analysis Figure 118. North America Peptide and Anticoagulant Drugs Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 119. North America Peptide and Anticoagulant Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 120. Europe Peptide and Anticoagulant Drugs Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 121. Europe Peptide and Anticoagulant Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 122. Latin America Peptide and Anticoagulant Drugs Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 123. Latin America Peptide and Anticoagulant Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 124. Middle East and Africa Peptide and Anticoagulant Drugs Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 125. Middle East and Africa Peptide and Anticoagulant Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 126. Asia Pacific Peptide and Anticoagulant Drugs Sales (K Units) and Growth Rate Forecast (2021-2026) Figure 127. Asia Pacific Peptide and Anticoagulant Drugs Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 128. Bottom-up and Top-down Approaches for This Report Figure 129. Data Triangulation Figure 130. Key Executives Interviewed

Celsus Baxter Hemmo Pharma Biofer Wockhardt AmbioPharm Bachem Sun Pharmaceutical Industries Pfizer Abbott Laboratories Leo Pharma Aspen Takeda Teva Sanofi Eli Lilly Novo Nordisk